Key Summary
- A £42 million trial, titled Transform, has officially begun testing its first male participants to identify the safest and most effective screening methods for prostate cancer.
- The trial is evaluating a combination of PSA blood tests, fast MRI scans, and at-home genetic spit tests against current NHS diagnostic pathways.
- Following this initial phase, the most successful methods will be tested on a massive scale involving up to 300,000 men.
A £42 million trial, titled Transform, has officially begun testing its first male participants to identify the safest and most effective screening methods for prostate cancer and reduce health inequalities.
The trial is evaluating a combination of PSA blood tests, fast MRI scans, and at-home genetic spit tests against current NHS diagnostic pathways.
Following this initial phase, the most successful methods will be tested on a massive scale involving up to 300,000 men.
The project aims to revolutionize how the disease is detected, moving away from reactive testing toward a proactive, national screening model.
In the initial stage, men are visiting locations like the InHealth Community Diagnostic Centre in Ealing for PSA blood tests and fast MRI scans. Simultaneously, another group of participants is performing genetic spit tests at home.
This multi-pronged approach is designed to determine which method - or combination of methods - is most effective at identifying prostate cancer in its earliest, most treatable stages.
Black men are twice likely to develop prostate cancer and twice as likely to die from it.
To address this issue, one in ten men invited to take part in Tranform will be black, with the trial team working closely with black community leaders and organisations to ensure meaningful participation.
Laura Kerby, Chief Executive at Prostate Cancer UK, said: "We know that a safe and effective mass screening programme could save thousands of men’s lives, and it starts with these men walking through the door today and trialling these tests.
"They’re helping to build a future where prostate cancer is found early, consistently and fairly, and where no man’s diagnosis is left to chance."
Professor Hashim Ahmed, chief investigator of the Transform trial, said: “The men tested today mark the start of the biggest prostate cancer screening trial in over two decades. The size and quality of Trasform mean the data we’re collecting now will help us make prostate cancer diagnosis far safer and more effective for all men at risk, and will inform lifesaving research for decades to come.”
